

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

In re Entresto (Sacubitril/Valsartan) Patent  
Litigation

NOVARTIS PHARMACEUTICALS  
CORPORATION,

Plaintiff,

v.

HETERO USA INC., HETERO LABS  
LIMITED, HETERO LABS LIMITED  
UNIT III, MSN PHARMACEUTICALS  
INC., MSN LABORATORIES PRIVATE  
LIMITED, MSN LIFE SCIENCES  
PRIVATE LIMITED,

Defendants.

C.A. No. 20-2930-RGA

PUBLIC VERSION FILED: August 20, 2024

C.A. No. 19-2053-RGA

**NOVARTIS’S MOTION FOR A RULE 62(d) INJUNCTION PENDING APPEAL AND  
TEMPORARY RESTRAINING ORDER PENDING RESOLUTION OF THIS MOTION**

Plaintiff Novartis Pharmaceuticals Corporation (“Novartis” or “Plaintiff”) respectfully moves (i) under Fed. R. Civ. P. 62(d) for an injunction pending resolution of the ongoing appeal regarding U.S. Patent No. 8,101,659 (“the ’659 patent”), and (ii) under Fed. R. Civ. P. 65(b) for a temporary restraining order pending resolution of this motion against Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited (collectively, “MSN”). Alternatively, Novartis requests an injunction of short duration to permit it an opportunity to seek further injunctive relief from the United States Court of Appeals for the Federal Circuit. The grounds for Novartis’s Motion are more fully-stated in the accompanying Opening Brief and supporting materials filed contemporaneously herewith.

Date: August 2, 2024

McCARTER & ENGLISH, LLP

/s/ Daniel M. Silver

Daniel M. Silver (#4758)

Alexandra M. Joyce (#6423)

Renaissance Centre

405 N. King Street, 8th Floor

Wilmington, Delaware 19801

(302) 984-6300

dsilver@mccarter.com

ajoyce@mccarter.com

OF COUNSEL:

Nicholas N. Kallas

Christina Schwarz

Christopher E. Loh

Jared L. Stringham

VENABLE LLP

151 West 42<sup>nd</sup> Street

New York, New York 10036

(212) 307-5500

nkallas@venable.com

cschwarz@venable.com

cloh@venable.com

jlstringham@venable.com

*Attorneys for Plaintiff Novartis  
Pharmaceuticals Corporation*

**RULE 7.1.1 CERTIFICATION**


Pursuant to D. Del. LR 7.1.1, counsel for Plaintiff Novartis Pharmaceuticals Corporation certifies that counsel for the parties, including Delaware Counsel, discussed the subject matter of the foregoing motion and the relief sought, and that the parties have been unable to reach agreement.

/s/ Daniel M. Silver

Daniel M. Silver (#4758)

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**


In re Entresto (Sacubitril/Valsartan) Patent  
Litigation

C.A. No. 20-2930-RGA  


NOVARTIS PHARMACEUTICALS  
CORPORATION,

Plaintiff,

v.

C.A. No. 19-2053-RGA  


HETERO USA INC., HETERO LABS  
LIMITED, HETERO LABS LIMITED  
UNIT III, MSN PHARMACEUTICALS  
INC., MSN LABORATORIES PRIVATE  
LIMITED, MSN LIFE SCIENCES  
PRIVATE LIMITED,

Defendants.

**[PROPOSED] ORDER ENTERING INJUNCTION PENDING APPEAL AND  
TEMPORARY RESTRAINING ORDER**

Plaintiff Novartis Pharmaceuticals Corporation (“Novartis”) having moved for an injunction pending resolution of the ongoing appeal regarding U.S. Patent No. 8,101,659 (“the ‘659 patent”) and a temporary restraining order (the “Motion”), and the Court having conducted a hearing on August 9, 2024 on Plaintiffs’ Motion,

IT IS HEREBY ORDERED this \_\_\_\_\_ day of \_\_\_\_\_ 2024, as follows:

1. The Motion is **GRANTED**;
2. Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited (collectively, “MSN”), and their affiliates, subsidiaries, and each of their officers, agents, servants and employees and those acting in privity

or in concert with one or more of the MSN Defendants, are hereby enjoined from making, using, offering to sell, or selling in the United States, or importing into the United States MSN's ANDA products (ANDA No. 213748) until such time as a final judgment is entered by the Court in this action, or the Court orders otherwise.

3. Novartis shall post an unsecured bond in the amount of \$\_\_\_\_\_ within seven (7) days of this Order.
4. This Order shall remain in effect until further order of this Court or the Federal Circuit.
5. [Alternatively, MSN and their affiliates, subsidiaries, and each of their officers, agents, servants and employees and those acting in privity or in concert with one or more of the MSN Defendants, are hereby enjoined from making, using, offering to sell, or selling in the United States, or importing into the United States MSN's ANDA products (ANDA No. 213748) until August \_\_, 2024, to permit Novartis an opportunity to seek relief from the United States Court of Appeals for the Federal Circuit.]

---

UNITED STATES DISTRICT JUDGE

**CERTIFICATE OF SERVICE**

The undersigned counsel hereby certifies that true and correct copies of the foregoing document were caused to be served on August 2, 2024 on the following counsel in the manner indicated below.

**VIA EMAIL:**

Stamatios Stamoulis  
Richard C. Weinblatt  
STAMOULIS & WEINBLATT LLC  
800 N. West Street, Third Floor  
Wilmington, DE 19801  
(302) 999-1540  
stamoulis@swdelaw.com  
weinblatt@swdelaw.com

Ronald M. Daignault  
Richard Juang  
DAIGNAULT IYER LLP  
8618 Westwood Center Drive, Suite 150  
Vienna, VA 22182

*Attorneys for Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and  
MSN Life Science Private Limited*

Dated: August 2, 2024

/s/ Daniel M. Silver

Daniel M. Silver (#4758)